Amplia Therapeutics Limited Stock Buy Hold or Sell Recommendation
| INNMF Stock | USD 0.06 0.01 14.49% |
Assuming the 90 days horizon and your above-average risk tolerance, our recommendation regarding Amplia Therapeutics Limited is 'Strong Sell'. Macroaxis provides Amplia Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding INNMF positions.
Check out Amplia Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Amplia and provide practical buy, sell, or hold advice based on investors' constraints. Amplia Therapeutics Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
Amplia |
Execute Amplia Therapeutics Buy or Sell Advice
The Amplia recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Amplia Therapeutics Limited. Macroaxis does not own or have any residual interests in Amplia Therapeutics Limited or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Amplia Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Out of control | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Moves slightly opposite to the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Amplia Therapeutics Trading Alerts and Improvement Suggestions
| Amplia Therapeutics is way too risky over 90 days horizon | |
| Amplia Therapeutics has some characteristics of a very speculative penny stock | |
| Amplia Therapeutics appears to be risky and price may revert if volatility continues | |
| Amplia Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 2.99 M. Net Loss for the year was (3.64 M) with profit before overhead, payroll, taxes, and interest of 1.83 M. | |
| Amplia Therapeutics Limited has accumulated about 14.61 M in cash with (4.4 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 22.0% of the company shares are held by company insiders |
Amplia Therapeutics Returns Distribution Density
The distribution of Amplia Therapeutics' historical returns is an attempt to chart the uncertainty of Amplia Therapeutics' future price movements. The chart of the probability distribution of Amplia Therapeutics daily returns describes the distribution of returns around its average expected value. We use Amplia Therapeutics Limited price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Amplia Therapeutics returns is essential to provide solid investment advice for Amplia Therapeutics.
| Mean Return | 0.80 | Value At Risk | -23.64 | Potential Upside | 25.00 | Standard Deviation | 17.69 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Amplia Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Amplia Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Amplia Therapeutics or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Amplia Therapeutics' price will be affected by overall pink sheet market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Amplia pink sheet's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.86 | |
β | Beta against Dow Jones | -0.53 | |
σ | Overall volatility | 17.95 | |
Ir | Information ratio | 0.04 |
Amplia Therapeutics Volatility Alert
Amplia Therapeutics Limited is showing large volatility of returns over the selected time horizon. Amplia Therapeutics Limited is a penny stock. Although Amplia Therapeutics may be in fact a good investment, many penny pink sheets are subject to artificial price hype. Make sure you completely understand the upside potential and downside risk of investing in Amplia Therapeutics Limited. We encourage investors to look for signals such as message board hypes, claims of breakthroughs, email spams, sudden volume upswings, and other similar hype indicators. We also encourage traders to check biographies and work history of company officers before investing in instruments with high volatility. You can indeed make money on Amplia instrument if you perfectly time your entry and exit. However, remember that penny pink sheets that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Amplia Therapeutics Fundamentals Vs Peers
Comparing Amplia Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Amplia Therapeutics' direct or indirect competition across all of the common fundamentals between Amplia Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Amplia Therapeutics or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of Amplia Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Amplia Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Amplia Therapeutics to competition |
| Fundamentals | Amplia Therapeutics | Peer Average |
| Return On Equity | -0.33 | -0.31 |
| Return On Asset | -0.19 | -0.14 |
| Profit Margin | (1.75) % | (1.27) % |
| Operating Margin | (1.75) % | (5.51) % |
| Current Valuation | 4.82 M | 16.62 B |
| Shares Outstanding | 194.01 M | 571.82 M |
| Shares Owned By Insiders | 22.09 % | 10.09 % |
| Shares Owned By Institutions | 23.14 % | 39.21 % |
| Price To Earning | (1.12) X | 28.72 X |
| Price To Book | 0.60 X | 9.51 X |
| Price To Sales | 3.97 X | 11.42 X |
| Revenue | 2.99 M | 9.43 B |
| Gross Profit | 1.83 M | 27.38 B |
| EBITDA | (3.64 M) | 3.9 B |
| Net Income | (3.64 M) | 570.98 M |
| Cash And Equivalents | 14.61 M | 2.7 B |
| Cash Per Share | 0.08 X | 5.01 X |
| Total Debt | 2.1 M | 5.32 B |
| Debt To Equity | 0.1 % | 48.70 % |
| Current Ratio | 31.18 X | 2.16 X |
| Book Value Per Share | 0.1 X | 1.93 K |
| Cash Flow From Operations | (4.4 M) | 971.22 M |
| Earnings Per Share | (0.02) X | 3.12 X |
| Number Of Employees | 25 | 18.84 K |
| Beta | 0.4 | -0.15 |
| Market Capitalization | 12.13 M | 19.03 B |
| Total Asset | 24.48 M | 29.47 B |
| Retained Earnings | (113 M) | 9.33 B |
| Working Capital | 8 M | 1.48 B |
| Current Asset | 9 M | 9.34 B |
| Current Liabilities | 1000 K | 7.9 B |
| Z Score | -2.6 | 8.72 |
| Net Asset | 24.48 M |
Amplia Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Amplia . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.86 | |||
| Day Median Price | 0.059 | |||
| Day Typical Price | 0.059 | |||
| Price Action Indicator | (0.01) | |||
| Period Momentum Indicator | (0.01) | |||
| Relative Strength Index | 34.96 |
About Amplia Therapeutics Buy or Sell Advice
When is the right time to buy or sell Amplia Therapeutics Limited? Buying financial instruments such as Amplia Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Amplia Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Chemicals Thematic Idea Now
Chemicals
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Chemicals theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Chemicals Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Amplia Pink Sheet
Amplia Therapeutics financial ratios help investors to determine whether Amplia Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Amplia with respect to the benefits of owning Amplia Therapeutics security.